MergerLinks Header Logo

Submit Deal

Submit Deal

Announced

Completed

RA Capital Management led a $27m Series B round in Vaxess.

Synopsis

RA Capital Management, an investment company, led a $27m Series B round in Vaxess, a life sciences company developing a sustained-release vaccine patch, with participation from The Engine, Mission BioCapital, and Global Health Investment Corporation. The company intends to use the funds to support its recently-launched phase 1 trial for the H1 influenza vaccine delivered by VX-103.

Principals

VAXESS

target

VAXESS

The Engine

bidder

The Engine

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (5)

Service Providers

Sort

Katie Rae

Katie Rae

ManagerManaging Partner at THE ENGINE
Deal Bio
Total Deals
6/
Total Value
£329M
Michael Schrader

Michael Schrader

ManagerCEO at VAXESS
Deal Bio
Total Deals
1/
Total Value
£24M
Peter Kolchinsky

Peter Kolchinsky

InvestorManaging Partner at RA CAPITAL MANAGEMENT
Deal Bio
Total Deals
35/
Total Value
£5,666M
Steve Tregay

Steve Tregay

ManagerCEO at MISSION BIOCAPITAL
Deal Bio
Total Deals
1/
Total Value
£24M
Labeeb Abboud

Labeeb Abboud

ManagerChairman and CEO at GLOBAL HEALTH INVESTMENT CORPORATION
Deal Bio
Total Deals
3/
Total Value
£77M

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US